Autopsy report · NCT05323110

Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

“Portfolio reprioritization”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 56 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Capella Bioscience Ltd

Sponsor type

Industry

Conditions

Chronic Inflammatory Disease

Interventions

CBS001; Placebo

Participants

56

Sites

1

Countries

United Kingdom

Trials that died the same way

• A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
  “Portfolio re-prioritization” (73% match in meaning)
• Safety Study of SEA-CD40 in Cancer Patients
  “Study closed due to portfolio prioritization” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.